LAM Pharmaceutical Corp, announced that Ixora Bio Medical Company Inc., a licensee of LAM, has commenced commercial sales of its first product, "Ixora for Women", a non-prescription female sexual enhancement product Ixora.

John Easton, chief executive officer of Ixora Bio Medical, stated, "The commercial release of "Ixora for Women" in the United States and Canada comes at a time when the medical community, media and public are recognizing that sexual health and optimal sexual function are an essential component of one's overall well being. Easton continued, "Having completed four years of extensive development, "Ixora for Women" is ready to answer the rapidly increasing demand for an upscale product that addresses the issue of women's sexual function."

Easton concluded, "With "Ixora for Women" available through doctors' offices, women's health clinics, direct sales and on the Ixora's web site, Ixora expects that the market size and strong demand backed by the upcoming media launch will all contribute to strong sales ramp up throughout 2004."

Dr. Jack Barkin, Urologist-in-chief and chief of surgery at the Humber River Regional Hospital in Toronto, Canada stated, "Women, especially as they reach menopause, have a loss of hormonal support that contributes to decreased sexual desire. The introduction of "Ixora for Women" provides women and their partners a natural solution to sexual enhancement." Joseph Slechta, president and chief executive officer of LAM, remarked, "We are pleased that Ixora has commenced commercial sales, marking the third product introduction based on LAM's proprietary IPM technology. As LAM's IPM Wound Gel, our veterinary product, and "Ixora for Women" all gain acceptance in their markets, we look forward to developing more products based on our remarkable technology."